Novartis Plans To Spin Off Generics Division Sandoz
Swiss pharma firm Novartis has said it plans to spin off its generics and biosimilars division Sandoz into a separate entity to allow both companies to pursue their own growth strategies.
This content was published on August 25, 2022 - 09:33 August 25, 2022 - 09:33 Keystone-SDA/jdpThe decision was in the best interest of shareholders, said Novartis CEO Vas Narasimhan in a media call on Thursday.
Late last year the Basel-based company said it was conducting a strategic review of Sandoz and considering all options, including spinning off the company into a separate entity. Many analysts predicted an IPO was the most likely scenario. Sandoz reaped $9.8 billion (CHF9.4 billion) in worldwide sales last year, but it has seen revenue decline in its key market in the US.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.

Comments
No comment